Research Highlights

August 10, 2021 Research Highlights

Hospitalization as a Reachable Moment for Patients with Opioid Use Disorder

Imagine a medication that reduces morbidity and mortality from a disease that affects more than two million people in the United States. The medication drastically improves quality of life for those who take it and reduces costs to the health care system. For hospitalized patients, this medication decreases the chance of being readmitted and of […]

July 26, 2021 Research Highlights

Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use

Prescription drug monitoring programs (PDMPs) are statewide databases that track controlled substances dispensed at retail pharmacies. Used by health care providers, public health officials, and other stakeholders, PDMPs have become a major tool in addressing unsafe opioid prescriptions. Robust features of PDMPs—including mandates that allow prescriber use of PDMP, data-sharing across states, and prescriber delegation of […]

July 23, 2021 Research Highlights

Prescription Opioids Dispensed to Patients with Cancer with Bone Metastasis: 2011-2017

In the past decade, opioid prescribing in the United States has steadily decreased as federal and state officials implemented strict regulations on prescription opioids to address the opioid crisis. The downward trend sparked concerns of undertreating chronic pain and prompted the Centers for Disease Control and Prevention (CDC) to formally clarify that the 2016 CDC […]

June 28, 2021 Research Highlights

Hepatitis C Treatment by Non-specialist Providers in the Direct-acting Antiviral Era

Direct-acting antiviral agents (DAAs), highly effective treatments for hepatitis C virus infection (HCV), transformed HCV therapy and made it easier for non-specialist providers to prescribe HCV treatment. Despite this simplification, many insurers include being a specialist as part of prior authorization requirements for DAA treatment. CHERISH Research Affiliate and former pilot grant recipient Shashi N. […]

June 16, 2021 Research Highlights

Prescription Drug Monitoring Program Mandates Affect Use of Opioids to Treat Acute, Severe Pain

Prescription drug monitoring programs (PDMP) have been crucial tools to address unsafe opioid prescribing. High rates of prescribing stoked the flames of the opioid crisis in the early 2000s, but opioid prescriptions have steadily decreased over the past decade. Unfortunately, opioid-related deaths have continued to rise each year. Many states have enacted comprehensive mandates that all clinicians consult the PDMP […]

June 16, 2021 Research Highlights

Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review

In this systematic review, researchers affiliated with the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) including CHERISH staff Erica Onuoha and Jared Leff; CHERISH investigators Bruce R. Schackman, Kathryn E. McCollister, and Sean M. Murphy; and CHERISH Advisory Board member Daniel Polsky, identified new studies supporting buprenorphine and methadone as economically advantageous medications for […]

June 4, 2021 Research Highlights

Characterizing Initiation, Use, and Discontinuation of Extended-Release Buprenorphine in a Nationally Representative United States Commercially Insured Cohort

Medications for opioid use disorder (MOUD) are evidence-based treatments that help people reduce or stop using opioids. However, high discontinuation rates of MOUD pose a barrier to reducing opioid-related overdoses. Extended-release buprenorphine (XR-BUP) is a relatively new MOUD, approved in late 2017, that has the potential to increase retention because of its monthly dosing schedule. Currently, there is […]

April 19, 2021 Research Highlights

Harmonizing Healthcare and Other Resource Measures for Evaluating Economic Costs in Substance Use Disorder Research

Lindsay Allen, PhD, MA, Feinberg School of Medicine at Northwestern University The National Institute on Drug Abuse, or NIDA, considers data harmonization in substance use disorder, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) research a high-priority. Data harmonization allows investigators to synthesize data across independent studies and promote more rigorous and comparable analyses of […]

January 26, 2021 Research Highlights

Inpatient care versus outpatient MOUD treatment for individuals with OUD

In a new study in JAMA Network Open, CHERISH investigators Jake Morgan, Sean Murphy, Alexander Walley, Benjamin Linas and Bruce Schackman and colleagues, examined whether rates of opioid-related overdose and all-cause hospitalization differed after outpatient medication treatment or inpatient care for opioid use disorder. They studied individuals who had received one of three federally- approved medications […]

December 14, 2020 Research Highlights

More X-Waivered Obstetrician-Gynecologists Needed to Address Opioid Epidemic

“X-the X Waiver” has been the slogan used by physicians and public health advocates fighting for greater access to buprenorphine, a medication proven to treat opioid use disorder (OUD) with higher effectiveness than many other treatments. Despite being safe, however, buprenorphine is tightly regulated, and to prescribe it, health care providers need a permit (the X-waiver) […]

November 25, 2020 Research Highlights

Healthcare utilization patterns among persons who use drugs during the COVID-19 pandemic

The COVID-19 pandemic has changed the way individuals access the healthcare system. For example, recent studies suggest high-risk populations may be foregoing necessary care out of fear of entering healthcare facilities and contracting the virus. A new study by Sean Murphy, PhD, associate professor of population health sciences at Weill Cornell Medicine and director of the methodology core […]

November 9, 2020 Research Highlights

Dissemination Science to Advance the Use of Simulation Modeling

COVID-19 has brought simulation modeling to the foreground of public discourse, as policy makers and stakeholders project the effects of different interventions to “flatten the curve.” Simulation models allow investigators to tinker with different conditions of the world to observe how they affect future outcomes; however, translating the models’ results to the public can be […]

Engage with CHERISH

Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.